Drugs / enisamium
enisamium
also known as
Enisamium Iodide · FAV00A · N-methyl-4-benzylcarbamidopyridinium iodide · Carbabenzpyride · Enisamium cation · Enisamium ion
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04682444 | Apr 2009 → Jan 2010 | influenza | Joint Stock Company "Farmak" | Completed | Mixed |
| Phase 31 trial | ||||||
| Phase 3 | NCT04682873 | May 2020 → Mar 2021 | COVID-19 | Joint Stock Company "Farmak" | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-01-22 | Joint Stock Company "Farmak" | Results Фармак завершив вивчення механізму антивірусної дії енісаміуму йодиду (Амізон) проти SARS-CoV-2 та одержав проміжні результати фази 3 клінічних досліджень у лікуванні пацієнтів з COVID-19 середньої важкості farmak.ua ↗
Станом на середину січня 2021 року здійснено проміжний аналіз багатоцентрового, подвійного-сліпого, рандомізованого, плацебо-контрольованого дослідження ефективності та безпеки препарату АМІЗОН® МАКС виробництва АТ «Фармак» у терапії пацієнтів з COVID-19 середнього ступеню важкості. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-01-22 | Joint Stock Company "Farmak" | Фармак завершив вивчення механізму антивірусної дії енісаміуму йодиду (Амізон) проти SARS-CoV-2 та одержав проміжні результати фази 3 клінічних досліджень у лікуванні пацієнтів з COVID-19 середньої важкості farmak.ua ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | enisamium | “Enisamium iodide (laboratory code FAV00A, trade name Amizon) is an antiviral, marketed in countries of the Commonwealth of Independent States for the treatment of viral...” PMID 33558285 ↗ Mar 2021 |
| Known as | Carbabenzpyride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1740071 ↗ |
| Known as | Enisamium cation | ChEMBL registry synonym — accepted as the source's own label CHEMBL1740071 ↗ |
| Known as | Enisamium Iodide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04682873 ↗ |
| Known as | Enisamium ion | ChEMBL registry synonym — accepted as the source's own label CHEMBL1740071 ↗ |
| Known as | FAV00A | “Enisamium iodide (laboratory code FAV00A, trade name Amizon) is an antiviral, marketed in countries of the Commonwealth of Independent States for the treatment of viral...” PMID 33558285 ↗ Mar 20211“the drug Amizon® Max (N-methyl-4-benzylcarbamidopyridinium iodide, international nonproprietary name enisamium iodide, lab code FAV00A)” NCT04682873 ↗ |
| Known as | N-methyl-4-benzylcarbamidopyridinium iodide | “This randomized, single-blind, clinical study was conducted to investigate the clinical efficacy and safety of the drug Amizon (N-methyl-4-benzylcarbamidopyridinium iodide,...” NCT04682444 ↗1“the drug Amizon® Max (N-methyl-4-benzylcarbamidopyridinium iodide, international nonproprietary name enisamium iodide, lab code FAV00A)” NCT04682873 ↗ |
| Action | Inhibit | “Enisamium can directly inhibit influenza viral RNA replication.” NCT04682444 ↗ |
| Modality | Small molecule | “Enisamium iodide is an antiviral small molecule.” NCT04682444 ↗ |
| Route | Oral | “Patients ingested Amizon tablets without chewing, after meal” NCT04682444 ↗ |